Technical Analysis for CALT - Calliditas Therapeutics AB
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Up |
| Historical CALT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bearish Engulfing | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| New 52 Week Closing High | Bullish | -1.83% | |
| Pocket Pivot | Bullish Swing Setup | -1.83% | |
| Upper Bollinger Band Walk | Strength | -1.83% | |
| Inside Day | Range Contraction | -1.83% | |
| Wide Bands | Range Expansion | -1.83% | |
| Pocket Pivot | Bullish Swing Setup | -0.95% | |
| Calm After Storm | Range Contraction | -0.95% | |
| Upper Bollinger Band Walk | Strength | -0.95% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Drug Manufacturers—Specialty & Generic
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Health Pharmaceutical Pharmaceutical Industry Pharmacy Medication Pharmaceutical Products Health Sciences Kidney Diseases Kidney Disease Pharmaceutics
Health Pharmaceutical Pharmaceutical Industry Pharmacy Medication Pharmaceutical Products Health Sciences Kidney Diseases Kidney Disease Pharmaceutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.97 |
| 52 Week Low | 19.0 |
| Average Volume | 34,032 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 21.00 |
| 10-Day Moving Average | 22.57 |
| Average True Range | 1.14 |
| ADX | 0.0 |
| +DI | 29.59 |
| -DI | 11.40 |
| Chandelier Exit (Long, 3 ATRs ) | 21.54 |
| Chandelier Exit (Short, 3 ATRs ) | 22.43 |
| Upper Bollinger Band | 24.75 |
| Lower Bollinger Band | 17.26 |
| Percent B (%b) | 0.81 |
| BandWidth | 35.62 |
| MACD Line | 1.57 |
| MACD Signal Line | 1.04 |
| MACD Histogram | 0.5315 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.35 | ||||
| Resistance 3 (R3) | 25.38 | 24.74 | 25.01 | ||
| Resistance 2 (R2) | 24.74 | 24.23 | 24.72 | 24.90 | |
| Resistance 1 (R1) | 24.04 | 23.91 | 23.72 | 24.01 | 24.79 |
| Pivot Point | 23.40 | 23.40 | 23.24 | 23.39 | 23.40 |
| Support 1 (S1) | 22.71 | 22.89 | 22.39 | 22.68 | 21.90 |
| Support 2 (S2) | 22.07 | 22.58 | 22.05 | 21.79 | |
| Support 3 (S3) | 21.37 | 22.07 | 21.68 | ||
| Support 4 (S4) | 21.34 |
